Senescence-associated mitochondrial dysfunction as a therapeutic target in ovarian cancer: Challenges and opportunities.

Khalili HS, Abadi B, Rezaei N

Open source

DOI
10.1016/j.ejphar.2026.179250
Published
2026 Sep 10
Container
European journal of pharmacology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ejphar.2026.179250,
  title = {Senescence-associated mitochondrial dysfunction as a therapeutic target in ovarian cancer: Challenges and opportunities.},
  author = {Khalili HS and Abadi B and Rezaei N},
  year = {2026},
  journal = {European journal of pharmacology},
  doi = {10.1016/j.ejphar.2026.179250},
  url = {https://doi.org/10.1016/j.ejphar.2026.179250}
}

RIS

TY  - JOUR
TI  - Senescence-associated mitochondrial dysfunction as a therapeutic target in ovarian cancer: Challenges and opportunities.
AU  - Khalili HS
AU  - Abadi B
AU  - Rezaei N
PY  - 2026
JO  - European journal of pharmacology
DO  - 10.1016/j.ejphar.2026.179250
UR  - https://doi.org/10.1016/j.ejphar.2026.179250
ER  - 

APA

HS, K., B, A., & N, R. (2026). Senescence-associated mitochondrial dysfunction as a therapeutic target in ovarian cancer: Challenges and opportunities.. European journal of pharmacology. https://doi.org/10.1016/j.ejphar.2026.179250

Source records